In this issue:
Immunotherapy in patients with NSCLC on baseline corticosteroids
Neoadjuvant erlotinib for stage IIIA-N2 EGFR-mutant NSCLC
5-year survival with pembrolizumab in advanced NSCLC
PD-(L)1 blockade + osimertinib: severe irAEs
Long-term follow-up of durvalumab in advanced NSCLC
Defining HPD treated with ICIs based on volumetric measurement
Surgery vs RT for stage I lung cancer
Plasma genotyping in ROS1+ NSCLC
Utility of CSF cfDNA as liquid biopsy
Outcome of NSCLC with BMs treated with ICIs
Please login below to download this issue (PDF)